Taysha joins lay­off wave as Dal­las biotech paus­es most of its R&D work

Un­for­tu­nate­ly, March couldn’t end with­out an­oth­er round of lay­offs in the drug de­vel­op­ment in­dus­try. As many as an­oth­er 62 life sci­ence work­ers will be search­ing for jobs af­ter Taysha Gene Ther­a­pies be­came the lat­est in a long string of bio­phar­mas to stum­ble this month.

A year and a half in­to its pub­lic life, Taysha is culling its work­force and prun­ing its near­ly 30-pro­gram CNS-fo­cused pipeline to stay afloat longer. The Dal­las biotech fol­lowed the suit of Zosano, Ovid, Paci­ra, Pas­sage, Adap­tive and Athenex.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER